blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3962955

EP3962955 - ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  04.02.2022
Database last updated on 03.06.2024
FormerThe international publication has been made
Status updated on  06.11.2020
Most recent event   Tooltip13.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Atara Biotherapeutics, Inc.
611 Gateway Blvd.
Suite 900
South San Francisco, CA 94080 / US
[2022/10]
Inventor(s)01 / AFTAB, Blake, T.
611 Gateway Blvd., Suite 900
South San Francisco, CA 94080 / US
 [2022/10]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
[2022/10]
Application number, filing date20798656.329.04.2020
[2022/10]
WO2020US30435
Priority number, dateUS201962840774P30.04.2019         Original published format: US 201962840774 P
[2022/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020223327
Date:05.11.2020
Language:EN
[2020/45]
Type: A1 Application with search report 
No.:EP3962955
Date:09.03.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 05.11.2020 takes the place of the publication of the European patent application.
[2022/10]
Search report(s)International search report - published on:IL05.11.2020
(Supplementary) European search report - dispatched on:EP20.04.2023
ClassificationIPC:C07K16/28, C07K16/46, C12N5/0783, A61K35/28, A61K39/395, A61P35/02, A61K31/7088, A61K35/15, A61K35/17, A61K39/00, C07K14/725
[2023/21]
CPC:
A61P35/02 (EP,IL,US); C12N5/0636 (EP,IL,KR); C07K14/7051 (EP,IL,KR,US);
C07K16/2803 (EP,IL,KR,US); A61K31/7088 (EP,IL); A61K35/17 (US);
A61K39/4611 (EP,IL,KR); A61K39/4631 (EP,IL,KR); A61K39/464412 (EP,IL,KR);
A61K39/464838 (EP,IL,KR); A61P35/00 (KR,US); C07K14/70517 (US);
C07K14/70521 (KR,US); C07K14/70578 (KR,US); A61K2039/505 (US);
A61K2039/5156 (US); A61K2039/5158 (US); A61K2239/38 (EP,IL,KR);
A61K2239/48 (EP,IL,KR); A61K38/00 (US); C07K2317/31 (US);
C07K2317/622 (EP,IL,KR,US); C07K2317/76 (US); C07K2319/02 (KR,US);
C07K2319/03 (EP,IL,KR,US); C07K2319/33 (EP,IL,US); C12N2510/00 (EP,IL,KR);
Y02A50/30 (EP) (-)
Former IPC [2022/10]C07K16/28, C07K16/46, C12N5/0783, A61K35/28, A61K39/395, A61P35/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/10]
TitleGerman:ANTIGENSPEZIFISCHE GEGEN CD19 GERICHTETE CAR-T-ZELLEN[2022/10]
English:ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS[2022/10]
French:CELLULES CAR-T CIBLÉES PAR UN ANTIGÈNE CD19 SPÉCIFIQUE[2022/10]
Entry into regional phase25.11.2021National basic fee paid 
25.11.2021Search fee paid 
25.11.2021Designation fee(s) paid 
25.11.2021Examination fee paid 
Examination procedure25.11.2021Examination requested  [2022/10]
20.11.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
16.03.2022Renewal fee patent year 03
14.03.2023Renewal fee patent year 04
13.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2016164731  (NOVARTIS AG [CH], et al) [I] 1-20* SEQ ID NO: 115;; figure 1; claims 1-53 *;
 [I]WO2018067992  (NOVARTIS AG [CH], et al) [I] 1-20 * page 454; claim 80; table 11; sequence 771 *;
 [I]WO2018132494  (INTREXON CORP [US]) [I] 1-20 * SEQ ID NO: 210, claim 19, [0248-0255];; claims 1-160 *
International search[Y]US2016362472  (BITTER HANS [US], et al) [Y] 5, 26 * Sequence 111 *;
 [Y]WO2017027291  (SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RES INSTITUTE) [US]) [Y] 42-55 * Paragraphs 32-33 and figures 3 and 4,paragraph 39, figure 9,paragraph 46 and figure 11, (paragraph 11 *;
 [XY]  - KOCHENDERFER, JAMES N. et al., "B- cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti- CD 19 chimeric-antigen-receptor- transduced T cells", Blood, The Journal of the American Society of Hematology 119.12, doi:10.1182/blood-2011-10-384388, (20120322), pages 2709 - 2720, URL: https://ashpublications.org/blood/article/119/12/2709/29857/B-cell-depletion-and-remissions-of-malignancy, XP055145503 [X] 1-4, 6-12, 16, 17, 24, 25, 28-37, 66, 67, 69-74 * The whole document The whole documentI * [Y] 5, 13-15, 18-27, 38-65, 68, 73-82

DOI:   http://dx.doi.org/10.1182/blood-2011-10-384388
 [XY]  - KOCHENDERFER, JAMES N. et al., "Construction and pre-clinical evaluation of an anti-CD 19 chimeric antigen receptor", Journal of immunotherapy, Hagerstown, Md., vol. 32.7, (20090930), page 689, URL: https://journals.lww.eom/immunotherapy-journal/Abstract/2009/09000/Construction_and_Preclinical_Evaluation_of_an.2.aspx, XP009133189 [X] 1-4, 6-12, 16, 17, 24, 25,28-37,66, 67, 69-74 * The whole document * [Y] 5, 13-15, 18-27, 38-65, 68, 73-82
 [Y]  - BOUCHER, JUSTIN C. et al., "Mutation of the CD 28 costimulatory domain confers decreased CAR T cell exhaustion", Blo od, vol. 132, no. 1, (20180000), pages 966 - 966, URL: https://ashpublications.org/blood/article/132/Supplement%201/966/266122/Mutation-of-the-CD28-Costimulatory-Domain-Confers, XP055145503 [Y] 13-15,56-58 * This document teaches that incorporating null mutations of the CD28 subdomains (YMNM, PRRP, or PYAP) optimizes CAR T cell signaling and reduces exhaustion (see the whole document). 29 Nov 2018 (2018/11/29) The whole document *

DOI:   http://dx.doi.org/10.1182/blood-2011-10-384388
 [Y]  - Justin C. Boucher, Gongbo Li, Bishwas Shrestha, Yongliang Zhang, Paresh Vishwasrao, Maria L. Cabral, Lawrence Guan and Marco L. Davila, "Mutation of the CD 28 costimulatory domain confers increased CAR T cell persistence and decreased exhaustion", The Journal of Immunology, US , vol. 200, no. 1 Supplement, ISSN 0022-1767, page 57.28, The Journal of Immunology, URL: https://www.jimmunol.org/content/200/1_Supplement/57.28, XP009532334 [Y] 13-15, 56-58 * The whole document *
 [Y]  - P. E. Love, S. M. Hayes, "ITAM-mediated Signaling by the T-Cell Antigen Receptor", Cold Spring Harbor Perspectives in Biology, (20100601), vol. 2, no. 6, doi:10.1101/cshperspect.a002485, pages a002485 - a002485, XP055171927 [Y] 18-21 * Table 2 *

DOI:   http://dx.doi.org/10.1101/cshperspect.a002485
 [Y]  - QIN, LE et al., "Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells", Journal of hematology & oncology, vol. 10.1, (20130313), pages 1 - 11, URL: https://jhoonline.biomedcentral.eom/articles/10.1186/sl3045-017-0437-8, XP055756715 [Y] 22, 23, 59 * The whole document, especially page 2, second paragraph of the right column, Fig. 1 and the "Results" section *

DOI:   http://dx.doi.org/10.1186/s13045-017-0437-8
 [Y]  - "FMC63-28Z receptor protein [synthetic construct", GenBank, (20120611), Database accession no. ADM64594.1 [Y] 27 * The whole document *
 [Y]  - PULE, M. A. et al., "Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma", Nature medicine, vol. 14, no. 11, doi:10.1038/nm.1882, (20081102), page 1264, URL: https://www.nature.com/articles/nm.1882, XP055021755 [Y] 38-41, 68 * The whole document *

DOI:   http://dx.doi.org/10.1038/nm.1882
 [Y]  - RAFIQ, SARWISH et al., "Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo", Nature biotechnology, vol. 36.9, doi:10.1038/nbt.4195, (20181001), pages 847 - 856, URL: https://www.nature.com/articles/nbt.4195, XP055632711 [Y] 63-65 * The whole document *

DOI:   http://dx.doi.org/10.1038/nbt.4195
 [Y]  - ZHANG, YONGPING et al., "CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells", Frontiers of medicine, vol. 11.4, (20170617), pages 554 - 562, URL: https://link.springer.com/article/10.1007/s11684-017-0543-6, XP036378721 [Y] 60, 61, 78, 81, 82 * The whole document *

DOI:   http://dx.doi.org/10.1007/s11684-017-0543-6
 [Y]  - YOON, DOK HYUN et al., "Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T", International journal of molecular sciences, vol. 19.2, (20180124), page 340, URL: https://www.mdpi.com/1422-0067/19/2/340, XP002790925 [Y] 60-65, 75-82 * The whole document *

DOI:   http://dx.doi.org/10.3390/ijms19020340
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.